Abbildung 29: Telmisartan - HCTZ
Reported here are selected arms from an 8-week, 4 x 5 factorial, multicentre, double-blind, placebo-controlled, dose-finding study conducted in 818 patients with mild-to-moderate hypertension.1 Patients were randomized to telmisartan 20 mg, 40 mg, 80 mg or 160 mg alone or in combination with HCTZ 6.25 mg, 12.5 mg, or 25 mg, giving a total of 20 treatment groups. SBP was significantly lowered with telmisartan 40 mg/HCTZ 12.5 mg compared with telmisartan 40 mg or HCTZ 12.5 mg monotherapies (P<0.01), and was significantly lowered with telmisartan 80 mg/HCTZ 12.5 mg compared with telmisartan 40/80 mg or HCTZ 12.5 mg monotherapies (P<0.01). 1. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833–850.